

CelgeneRiskManagement.com

Login Page



Welcome to the Celgene REMS Program

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID[®] (thalidomide), REVLIMID[®] (lenalidomide) and POMALYST[®] (pomalidomide). The THALOMID REMS[®] program (formerly known as the S.T.E.P.S.[®] program), REVLIMID REMS[®] program (formerly known as the RevAssist[®] program) and POMALYST REMS[®] program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:

RevlimidREMS[®]

Visit www.REVLIMIDREMS.com,
to learn more about the
REVLIMID REMS[®] program.

PomalystREMS[®]

Visit www.POMALYSTREMS.com,
to learn more about the
POMALYST REMS[®] program.

THALOMIDREMS[®]

Visit www.THALOMIDREMS.com,
to learn more about the
THALOMID REMS[®] program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:

User Name

Password

[Forgot Password? >](#)

[Contact Us](#) | [Terms of Use](#) | [Privacy Policy](#)
© 2005-2015, Celgene Corporation

Home Page (after prescriber logon)

John Doe

Home Help Logout

Celgene Home

Click on a button below to access the corresponding REMS menu of operations for that product: enroll a patient, access an existing or save a new Patient-Physician Agreement Form, complete a prescriber survey or write a prescription.

For **REVLIMID REMS**[®]
(Formerly known as the RevAssist program)

RevlimidREMS[®]

Please see full [Prescribing Information](#), including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.REVLIMIDREMS.com, to learn more about the REVLIMID REMS[®] program.

For **POMALYST REMS**[®]

PomalystREMS[®]

Please see full [Prescribing Information](#), including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.POMALYSTREMS.com, to learn more about the POMALYST REMS[®] program.

For **THALOMID REMS**[®]
(Formerly known as the S.T.E.P.S. program)

THALOMIDREMS[®]

Please see full [Prescribing Information](#), including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.THALOMIDREMS.com, to learn more about the THALOMID REMS[®] program.

The Prescriber Dashboard is an optional resource that displays the status of patients under your care for a specific Celgene REMS program. A patient search function is also included to access detailed patient history information.

Select the "Manage My Account" button to view your Celgene REMS online account information.

Prescriber Dashboard Manage My Account

[Contact Us](#) | [Terms of Use](#) | [Privacy Policy](#)
© 2005-2015, Celgene Corporation

REVLIMID REMS module

The screenshot shows the Revlimid REMS Main Menu interface. At the top left, the user name "John Doe" is displayed. On the top right, there are three buttons: "Home", "Help", and "Logout". The main header area contains the "RevlimidREMS" logo on the left and "REVLIMID REMS® Main Menu" on the right. The menu consists of several blue buttons with icons and text:

- New PPAF/Patient Enrollment**: Nuevo formulario de acuerdo de paciente-médico/Inscripción de paciente
- Work with Saved/ Submitted PPAF Forms**: Trabajar con formulario de acuerdo de paciente-médico guardado/entregado (Click here for more options) / (Presione aquí para más opciones)
- Prescriber Survey**: Encuesta de prescriptor (Click here for new/next Rx) / (Presione aquí para la próxima/nueva prescripción)
- Standard Prescription Form**
- Veterans Administration Prescription Form**

At the bottom of the page, there are links for [Contact Us](#), [Terms of Use](#), and [Privacy Policy](#), followed by the copyright notice: © 2005-2016, Celgene Corporation.

RevlimidREMS®

REVLIMID REMS® Home

About REVLIMID REMS®

Important Safety Information

Full Prescribing Information

Patient Medication Guide

Prescriber Resources

Patient Resources

Pharmacist Resources

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Welcome to the REVLIMID REMS® program

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Important information about REVLIMID and the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program

- REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy.
- To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID REMS™" (formerly known as the RevAssist® program).
- Only prescribers and pharmacies certified by the REVLIMID REMS® program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS® program.

The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:

1. To prevent the risk of embryo-fetal exposure to REVLIMID
2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID

[Privacy policy](#) | [Terms of Use](#) | [Site map](#) | [Contact us](#)

REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2016 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.

- REVLIMID REMS® Home
- About REVLIMID REMS®
- Important Safety Information 
- Full Prescribing Information 
- Patient Medication Guide 
- Prescriber Resources
- Patient Resources
- Pharmacist Resources

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

About the REVLIMID REMS® program

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID Risk Evaluation and Mitigation Strategy (REMS)" (formerly known as the RevAssist® program). Only certified prescribers can prescribe REVLIMID and only certified pharmacies can dispense REVLIMID in the REVLIMID REMS® program.

In order to receive REVLIMID, all patients must be enrolled in the REVLIMID REMS® program and agree to comply with the requirements of the REVLIMID REMS® program.

Key points of the REVLIMID REMS® program

Prescriber

- The prescriber enrolls and becomes certified with Celgene for the REVLIMID REMS® program
- The prescriber counsels patient on benefits and risks of REVLIMID
- The prescriber provides contraception and emergency contraception counseling
- The prescriber verifies negative pregnancy test for all female patients of reproductive potential
- The prescriber completes a REVLIMID® (lenalidomide) Patient-Physician Agreement Form with each patient and sends to Celgene
- The prescriber/patient completes applicable mandatory confidential survey
- The prescriber obtains an authorization number from Celgene and writes it on every prescription, along with the patient risk category
- The prescriber writes no more than a 4-week (28-day) supply, with no automatic refills or telephone prescriptions
- The prescriber sends REVLIMID prescription to certified pharmacy

Pharmacy

- The pharmacy certifies with Celgene for the REVLIMID REMS® program
- The certified pharmacy must obtain a confirmation number from Celgene before dispensing
- The certified pharmacy counsels the patient, and completes an Education and Counseling Checklist
- The certified pharmacy dispenses REVLIMID to patient along with a Medication Guide

[Privacy policy](#) | [Terms of Use](#) | [Site map](#) | [Contact us](#)

REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
 © 2016 year of origin. Celgene Corporation, www.celgene.com.
 This website is intended for residents of the United States only.



- REVLIMID REMS® Home
- About REVLIMID REMS®
- Important Safety Information
- Full Prescribing Information
- Patient Medication Guide
- Prescriber Resources**
- Patient Resources
- Pharmacist Resources

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Prescriber Resources

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Enrolling in REVLIMID REMS®

In order to prescribe REVLIMID, you must enroll in the REVLIMID REMS® program (formerly known as the RevAssist® program) and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to Celgene Customer Care at 1-888-432-9325.

[Prescriber Enrollment Form](#)

Prescribing REVLIMID for your patients

In order to receive REVLIMID, your patients must also be enrolled in the REVLIMID REMS® program. You can enroll your patients, and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.

Additionally, you can also enroll your patients and write prescriptions by downloading the Desktop Software and installing it on your computer.

[Enroll Your Patients at CelgeneRiskManagement.com](#)

[Download the Celgene REMS mobile app](#)

[Patient Prescription Form](#)

[Desktop Software Installation](#) | [Installation User Guide](#)

Learning more about REVLIMID REMS®

For additional information about the REVLIMID REMS® program, please see the educational materials below.

[Prescriber Guide to REVLIMID REMS® Program](#)

[REVLIMID REMS® At-A-Glance](#)

[Full Prescribing Information](#)

Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods:

REPORTING TO CELGENE	
Email:	drugsafety@celgene.com
Telephone:	1-908-673-9667
Toll-free:	1-800-640-7854 (Global Drug Safety & Risk Management) or 1-888-423-5436 (Celgene Customer Care Center)
Fax:	1-908-673-9115
Mail to:	Global Drug Safety & Risk Management Celgene Corporation 300 Connell Dr. Suite 6000 Berkeley Heights, NJ 07922

REPORTING TO THE FDA	
Adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID may also be reported to the FDA MedWatch Reporting System using any of the following methods:	
Online:	https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm
Telephone:	1-800-FDA-1088
Fax:	1-800-FDA-0178
Mail to:	MedWatch 5600 Fishers Lane Rockville, MD 20852-9787



- REVLIMID REMS® Home
- About REVLIMID REMS®
- Important Safety Information 
- Full Prescribing Information 
- Patient Medication Guide 
- Prescriber Resources
- Patient Resources**
- Pharmacist Resources

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Patient Resources

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

What you need to know about the REVLIMID REMS® program

Your doctor will enroll you in the REVLIMID REMS® program (formerly known as the RevAssist® program) so that you can receive your medication. Use the materials below to learn more about the REVLIMID REMS® program, and what you need to do.

- [Patient Guide to REVLIMID REMS® Program](#) 
- [Guía para el paciente de REVLIMID REMS®](#) 
- [Patient Medication Guide](#) 
- [Visit Planned Parenthood site for Emergency Contraception Brochure](#)
- [Patient Survey Reminder Card](#) 

You can take your mandatory confidential patient survey at CelgeneRiskManagement.com by clicking the button below or by using the Celgene REMS mobile app.

[Patient Survey](#) 

[Privacy policy](#) | [Terms of Use](#) | [Site map](#) | [Contact us](#)

REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
 © 2016 year of origin, Celgene Corporation, www.celgene.com.
 This website is intended for residents of the United States only.



- REVLIMID REMS® Home
- About REVLIMID REMS®
- Important Safety Information
- Full Prescribing Information
- Patient Medication Guide
- Prescriber Resources
- Patient Resources
- Pharmacist Resources**

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Pharmacist Resources

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

REVLIMID REMS® information for certified pharmacies

REVLIMID is only dispensed from REVLIMID REMS® program (formerly known as the RevAssist® program) certified pharmacies. To learn more about how to become a certified pharmacy please contact the Celgene Customer Care at 1-888-423-5436.

As a REVLIMID REMS® certified pharmacy, you must follow the requirements of the REVLIMID REMS® program. You may download a guide to the program, a checklist for counseling patients, and the full prescribing information below.

Pharmacy Guide to REVLIMID REMS® Program

Full Prescribing Information

Education and Counseling Checklist for Pharmacies

Lista de verificación de educación y asesoramiento para farmacias

The Celgene REMS Pharmacy Portal

In addition to calling the Celgene Customer Care Center to obtain a confirmation number for a prescription, eligible pharmacies can obtain confirmation numbers using the Celgene REMS Pharmacy Portal at CelgeneREMSPharmacyPortal.com. Contact your Celgene Account Manager to see if your pharmacy is eligible.

Celgene REMS Pharmacy Portal

Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods:

REPORTING TO CELGENE

Email: drugsafety@celgene.com

Telephone: 1-908-673-9667

Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or 1-888-423-5436 (Celgene Customer Care Center)

Fax: 1-908-673-9115

Mail to: Global Drug Safety & Risk Management
Celgene Corporation
300 Connell Dr.
Suite 6000
Berkeley Heights, NJ 07922

REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID may also be reported to the FDA MedWatch Reporting System using any of the following methods:

Online: <https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm>

Telephone: 1-800-FDA-1088

Fax: 1-800-FDA-0178

Mail to: MedWatch
5900 Fishers Lane
Rockville, MD 20852-9787

- REVLIMID REMS® Home
- About REVLIMID REMS®
- Important Safety Information
- Full Prescribing Information
- Patient Medication Guide
- Prescriber Resources
- Patient Resources
- Pharmacist Resources

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Welcome to the REVLIMID REMS® program

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or no-response to erythropoietin-stimulating agents (ESA) in patients with a deletion 5q cytogenetic abnormality.

REVLIMID is also indicated for the treatment of patients with multiple myeloma (MCL) whose disease has not responded to bortezomib.

REVLIMID Risk Evaluation

The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:

1. To prevent the risk of embryo-fetal exposure to REVLIMID.
2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID.

You Are Now Leaving REVLIMIDREMS.com
Click "OK" to proceed or "CANCEL" to return to REVLIMIDREMS.com

OK CANCEL



[Privacy policy](#) | [Terms of Use](#) | [Site map](#) | [Contact us](#)

REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2016 year of origin, Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.



[REVLIMID REMS® Home](#)

[About REVLIMID REMS®](#)

[Important Safety Information](#) 

[Full Prescribing Information](#) 

[Patient Medication Guide](#) 

[Prescriber Resources](#)

[Patient Resources](#)

[Pharmacist Resources](#)

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Site map

[REVLIMID REMS® Home](#)

[About REVLIMID REMS®](#)

[Prescriber Resources](#)

[Patient Resources](#)

[Pharmacist Resources](#)

[Privacy policy](#) | [Terms of Use](#) | [Site map](#) | [Contact us](#)

REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2016 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.

